evidence: The incidence rate of the adverse event of constipation was higher in the sitagliptin group (2.3) than in the non-exposed group (1.8).
intervention: sitagliptin 100 mg/day
comparator: comparator agent
outcome: The incidence of the composite endpoint of rash